Altimmune, Inc.
Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024. In the quarter to June 2026, revenue grew 520.0%, EPS grew 55.6%, free cash flow fell 25.3% and total debt rose 142.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ALT
Altimmune, Inc. (ALT) Altman Z-score
Altimmune, Inc.'s Altman Z-score for fiscal 2025 is 0.23, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 0.23 | (12.22) |
| FY2024 | 12.45 | (5.80) |
| FY2023 | 18.25 | (0.22) |
| FY2022 | 18.47 | 9.27 |
| FY2021 | 9.20 | 0.88 |
| FY2020 | 8.32 | 10.49 |
| FY2019 | −2.17 | 1.91 |
| FY2018 | −4.08 | (0.83) |
| FY2017 | −3.25 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.94 | — | 1.13 | |
| Retained earnings / total assets | (2.32) | — | −3.25 | |
| EBIT / total assets | (0.34) | — | −1.11 | |
| Market value of equity / total liabilities | 5.78 | — | 3.47 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | 0.23 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | 0.63 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| OCS Oculis Holding AG compare | 10.5× |
| ALT Altimmune, Inc. | 0.2× |
| ARVN Arvinas, Inc. compare | −0.6× |
| ALLO Allogene Therapeutics, Inc. compare | −3.7× |
| PROK ProKidney Corp. compare | −5.9× |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | −30.4× |
| MPLT MapLight Therapeutics, Inc. compare | — |
| EPRX Eupraxia Pharmaceuticals Inc. compare | — |
| CTNM Contineum Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets